Compare Incyte Corporation (INCY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Star Bulk Carriers Corp — how do they compare? Incyte Corporation trades at $120.54 (market cap $24.54B), while Star Bulk Carriers Corp trades at $27.89 (market cap $3.09B). The key difference: Incyte Corporation is far larger — about 7.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SBLK | |
|---|---|---|
Market Cap | $24.54B | $3.09B |
Sector | Health | Industrials |
52-Week High | $129.93 | $29.15 |
52-Week Low | $81.61 | $16.79 |
Enterprise Value | $20.04B | $3.77B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Star Bulk Carriers (SBLK) trades at $27.81, down 2.15% on the day, but maintains a bullish technical outlook with strong support at $27. Fundamentally, the company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Revenue growth accelerated to $1.2 billion in 2026, driving a net margin of 23.86%. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though operations remain unaffected.
The outlook for SBLK is positive, supported by strong profitability, a healthy balance sheet with a debt-to-asset ratio of 27.84%, and a shareholder-friendly dividend policy. Risks include exposure to volatile dry bulk shipping rates and competitive pressures. Analyst consensus is bullish with 58.34% buy ratings, indicating confidence in continued earnings momentum and valuation appeal at a P/E of 10.85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
